Erasca, Inc. (ERAS) ROA
- 2026-06-30: ROA -66.02%.
- 2026-03-31: ROA -60.06%.
- 2025-12-31: ROA -31.44%.
- 2025-09-30: ROA -30.37%.
Complete source-backed roa history.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical ROA
| Date | ROA |
|---|
| 2026-06-30 | -66.02% |
|---|
| 2026-03-31 | -60.06% |
|---|
| 2025-12-31 | -31.44% |
|---|
| 2025-09-30 | -30.37% |
|---|
| 2025-06-30 | -28.80% |
|---|
| 2025-03-31 | -33.44% |
|---|
| 2024-12-31 | -32.17% |
|---|
| 2024-09-30 | -30.09% |
|---|
| 2024-06-30 | -30.11% |
|---|
| 2024-03-31 | -34.28% |
|---|
| 2023-12-31 | -31.63% |
|---|
| 2023-09-30 | -54.98% |
|---|
| 2023-06-30 | -53.49% |
|---|
| 2023-03-31 | -51.24% |
|---|
| 2022-12-31 | -47.15% |
|---|
| 2022-09-30 | -30.92% |
|---|
| 2022-06-30 | -33.41% |
|---|
| 2022-03-31 | -29.70% |
|---|
| 2021-12-31 | -24.48% |
|---|
| 2021-09-30 | -29.54% |
|---|
| 2021-06-30 | -56.44% |
|---|
| 2020-12-31 | -81.44% |
|---|
Annual ROA
| Date | ROA |
|---|
| 2025-12-31 | -31.44% |
|---|
| 2024-12-31 | -32.17% |
|---|
| 2023-12-31 | -31.63% |
|---|
| 2022-12-31 | -47.15% |
|---|
| 2021-12-31 | -24.48% |
|---|
| 2020-12-31 | -81.44% |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|